iDEA-TECH Awards 2025-2026

The Sanofi Innovations in Data Exploration, Analytics & Technology (iDEA-TECH) Awards program provides seed funding to innovators at research centers and early start-ups to transform breakthrough digital, data science tools and new technologies into solutions that accelerate the R&D pipeline and improve people’s lives.

Eligibility, Guidelines and General Terms

Eligibility

iDEA-TECH Awards is open to: 

  • Asia: start-ups, academics and university-affiliated hospitals (single-party submissions only; fee-for-service models are acceptable). No third party collaborators. 
  • North America: start-ups, academics, non-profits and medical centers (single-party submissions only; fee-for-service models are acceptable). No third party collaborators. 
  • Europe: start-ups, academic partners listed below (no third-party collaborators except between academic partners within the below network) 

 

 

Pre-Proposal Submission Guidelines

  • Coordinate with your Technology Transfer Office (TTO), Office of Sponsored Programs, Office of Corporate Partnership or business office that handles corporate sponsored research to ensure alignment with the program scope and compliance with application criteria (see rules page for details).
  • Pre-proposal submissions should be made by your TTO or business office. Pre-proposals must be non-confidential and clearly outline objectives and a 12-month work plan within the specified budget. 
  • Formatting requirements 
    • Use the official templates provided in the submission form. 
    • Text must be in Calibri, size 11, single-spaced. 
    • Save as a Word (.docx) document only. 
    • Adhere to all length restrictions specified in the template. 

 

General Terms

  • Applicants must 
    • Hold the necessary permission and/or license for all technologies used in the proposed work. 
    • Own the rights to share results with Sanofi for Sanofi's permitted use.
    • Grant Sanofi the right to an exclusive option to arising IP.
  • Publications: A key outcome of the program is to publish findings resulting from the collaboration following customary authorship guidelines. Sanofi requires limited review periods prior to submission or disclosure to protect any patentable information in a proposed publication. If a publication includes Sanofi confidential information or content requiring copyright or patent protection, it must be revised to remove sensitive material and/or allowed time for appropriate copyright registration or patent filing.